Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.38 |
| ▸ | HSD11B2 | P80365 | 5/20 | 0.38 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1117123 | 1.00 | KMT2A (0.39) | KMT2AHSD11B1HSD11B2SUV39H2MAPT | |
| SCHEMBL1117107 | 0.92 | KMT2A (0.41) | KMT2AHSD11B1HSD11B2SUV39H2MAPT | |
| SCHEMBL1117104 | 0.92 | KMT2A (0.41) | KMT2AHSD11B1HSD11B2SUV39H2MAPT | |
| SCHEMBL2098131 | 0.87 | KDM1A (0.42) | KMT2AHSD11B1HSD11B2SUV39H2MAPT | |
| SCHEMBL2098129 | 0.87 | KDM1A (0.42) | KMT2AHSD11B1HSD11B2SUV39H2MAPT | |
| SCHEMBL2612630 | 0.87 | KMT2A (0.37) | KMT2AHSD11B1HSD11B2SUV39H2MAPT | |
| SCHEMBL1116626 | 0.85 | OPRK1 (0.51) | KMT2AOPRK1KCNH2OPRM1OPRD1 | |
| SCHEMBL1116628 | 0.85 | OPRK1 (0.51) | KMT2AOPRK1KCNH2OPRM1OPRD1 | |
| SCHEMBL2620566 | 0.85 | USP2 (0.39) | OPRK1KCNH2OPRM1OPRD1 | |
| SCHEMBL1117088 | 0.81 | CXCR6 (0.47) | KMT2AOPRK1KCNH2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163771-B2 | 11 β-HSD1 modulators | EXELIXIS, INC. (US) | 2012-04-24 | — | — | US | claimed |
| EP-2280966-A1 | AZABICYCLO [3.2.1]OCTYL DERIVATIVES AS 11 BETA-HSD1 MODULATORS | Exelixis, Inc. (US) | 2011-02-09 | — | — | EP | claimed |
| US-20100105675-A2 | 11 BETA-HSD1 MODULATORS | EXELIXIS, INC. (US) | 2010-04-29 | — | — | US | claimed |
| US-20090247515-A1 | 11 Beta-HSD1 Modulators | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | claimed |
| WO-2009114173-A1 | AZABICYCLO [3. 2. I] OCTYL DERIVATIVES AS 11 BETA-HSDL MODULATORS | EXELIXIS, INC. (US) | 2009-09-17 | — | — | WO | claimed |
| US-8163771-B2 | 11 β-HSD1 modulators | EXELIXIS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100105675-A2 | 11 BETA-HSD1 MODULATORS | EXELIXIS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20090247515-A1 | 11 Beta-HSD1 Modulators | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105675-A2 | 11 BETA-HSD1 MODULATORS | HSD11B1, HSD11B2, HSD3B1 | KMT2A 2538/4885HSD11B1 1/4885HSD11B2 2/4885 |
| US-20090247515-A1 | 11 Beta-HSD1 Modulators | HSD11B1, HSD11B2, HSD3B1 | KMT2A 1907/4885HSD11B1 1/4885HSD11B2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.